Genmab and AbbVie’s Epkinly has met its dual primary endpoints as a second-line combination therapy in relapsed/refractory ...

Results from the Phase III EPCORE FL-1 trial (NCT05409066) showed that patients treated with Epkinly (epcoritamab) in ...

Epkinly with Rituxan and Revlimid, compared to Rituxan and Revlimid alone, reduced risk of progression or death by 79%.

Genmab and AbbVie are taking key steps toward moving their blood cancer drug Epkinly into earlier lines of treatment in follicular lymphoma (FL). | Genmab and AbbVie have presented new data that could ...

AbbVie is investing $195m to strengthen domestic API production, with the expansion of its manufacturing plant in North ...

The promising results, along with a separate FDA decision, could signal a major expansion of the use of the two companies' ...

Genmab A/S (NASDAQ:GMAB) is one of the top most undervalued biotech stocks to buy now. On August 7, William Blair analyst ...

Investing.com -- Shares of Genmab A/S (CSE: GMAB) rose after the Danish biotech company reported second-quarter earnings that beat expectations, driven by strong sales of Darzalex and positive trial ...

Danish biotech Genmab (Nasdaq: GMAB) and US partner AbbVie (NYSE: ABBV) have reported a decisive win in a Phase III study of ...

The current $195 million investment is part of a commitment to invest more than $10 billion for innovation and manufacturing capacity enhancement.

Genmab AS (GMAB) reports a 19% revenue increase and a 56% rise in operating profit, showcasing strong financial performance ...

Genmab reported strong Phase 3 trial results for epcoritamab in FL, secured FDA priority review, and raised its 2025 sales ...